Investment Management of Virginia LLC reduced its holdings in Natus Medical Inc (NASDAQ:BABY) by 4.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 65,823 shares of the medical equipment provider’s stock after selling 2,985 shares during the quarter. Investment Management of Virginia LLC owned approximately 0.21% of Natus Medical worth $2,515,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Benjamin F. Edwards & Company Inc. raised its holdings in Natus Medical by 2,085.6% during the third quarter. Benjamin F. Edwards & Company Inc. now owns 2,732 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 2,607 shares during the last quarter. SG Americas Securities LLC acquired a new position in Natus Medical during the third quarter worth $138,000. Flinton Capital Management LLC raised its holdings in Natus Medical by 82.0% during the second quarter. Flinton Capital Management LLC now owns 3,774 shares of the medical equipment provider’s stock worth $141,000 after buying an additional 1,700 shares during the last quarter. Greenwood Capital Associates LLC acquired a new position in Natus Medical during the fourth quarter worth $219,000. Finally, First Capital Advisors Group LLC. acquired a new position in Natus Medical during the fourth quarter worth $222,000. Hedge funds and other institutional investors own 99.64% of the company’s stock.
Several research analysts have weighed in on the stock. Benchmark restated a “buy” rating and set a $49.00 price objective (down previously from $55.00) on shares of Natus Medical in a report on Tuesday, January 16th. BidaskClub downgraded shares of Natus Medical from a “sell” rating to a “strong sell” rating in a report on Saturday, January 6th. William Blair downgraded shares of Natus Medical from an “outperform” rating to a “market perform” rating in a report on Monday, January 8th. Finally, Zacks Investment Research downgraded shares of Natus Medical from a “buy” rating to a “hold” rating in a report on Tuesday, December 26th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a buy rating to the company. Natus Medical presently has a consensus rating of “Hold” and an average target price of $47.00.
Natus Medical (NASDAQ:BABY) last released its quarterly earnings data on Wednesday, February 7th. The medical equipment provider reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.54 by ($0.12). Natus Medical had a negative net margin of 4.05% and a positive return on equity of 11.36%. The firm had revenue of $131.40 million during the quarter, compared to the consensus estimate of $131.38 million. During the same quarter last year, the business posted $0.51 earnings per share. Natus Medical’s revenue was up 22.0% compared to the same quarter last year. sell-side analysts expect that Natus Medical Inc will post 1.63 EPS for the current fiscal year.
Natus Medical Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.